Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.

Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkarinen J, Koffert J, Koivurova OP, Pesu M, Kivelä L, Lovró Z, Keisala J, Isola J, Parnes JR, Leon F, Mäki M.

Lancet Gastroenterol Hepatol. 2019 Sep 4. pii: S2468-1253(19)30264-X. doi: 10.1016/S2468-1253(19)30264-X. [Epub ahead of print]

PMID:
31494096
2.

Cytokeratin-supervised deep learning for automatic recognition of epithelial cells in breast cancers stained for ER, PR, and Ki-67.

Valkonen M, Isola J, Isola J, Ylinen O, Muhonen V, Saxlin A, Tolonen T, Nykter M, Ruusuvuori P.

IEEE Trans Med Imaging. 2019 Aug 7. doi: 10.1109/TMI.2019.2933656. [Epub ahead of print]

PMID:
31398111
3.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M.

Mol Cancer Ther. 2019 Jul 10. pii: molcanther.0207.2019. doi: 10.1158/1535-7163.MCT-19-0207. [Epub ahead of print]

PMID:
31292166
4.

Breast cancer outcome prediction with tumour tissue images and machine learning.

Turkki R, Byckhov D, Lundin M, Isola J, Nordling S, Kovanen PE, Verrill C, von Smitten K, Joensuu H, Lundin J, Linder N.

Breast Cancer Res Treat. 2019 Aug;177(1):41-52. doi: 10.1007/s10549-019-05281-1. Epub 2019 May 22.

5.

Intrafollicular paraoxonase 1 activity and the steroidogenic potential of the first post-partum dominant follicle in dairy cows.

Isola JVV, Velasco Acosta DA, Bespalhok Jacometo C, Rincón JAA, Silveira PAS, Corrêa MN, Schneider A.

Reprod Domest Anim. 2019 Jun;54(6):924-927. doi: 10.1111/rda.13442. Epub 2019 May 3.

PMID:
31004539
6.

Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.

Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J.

BMC Cancer. 2018 Oct 26;18(1):1045. doi: 10.1186/s12885-018-4917-1.

7.

Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas.

Luhtala S, Haapaniemi T, Staff S, Isola J.

Appl Immunohistochem Mol Morphol. 2018 Oct 24. doi: 10.1097/PAI.0000000000000716. [Epub ahead of print]

PMID:
30358612
8.

Optimized JPEG 2000 Compression for Efficient Storage of Histopathological Whole-Slide Images.

Helin H, Tolonen T, Ylinen O, Tolonen P, Näpänkangas J, Isola J.

J Pathol Inform. 2018 May 25;9:20. doi: 10.4103/jpi.jpi_69_17. eCollection 2018.

9.

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.

Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H.

BMC Cancer. 2018 May 2;18(1):504. doi: 10.1186/s12885-018-4418-2.

10.

Quantifying shorebird habitat in managed wetlands by modeling shallow water depth dynamics.

Schaffer-Smith D, Swenson JJ, Reiter ME, Isola JE.

Ecol Appl. 2018 Sep;28(6):1534-1545. doi: 10.1002/eap.1732. Epub 2018 Jul 19.

11.

Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies.

Koivusalo L, Kaipia A, Kujala P, Isola J, Tolonen TT.

Histol Histopathol. 2018 Apr;33(4):399-405. doi: 10.14670/HH-11-940. Epub 2017 Oct 23.

PMID:
29058306
12.

Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.

Veskimäe K, Staff S, Grönholm A, Pesu M, Laaksonen M, Nykter M, Isola J, Mäenpää J.

Tumour Biol. 2016 Sep;37(9):11991-11999. Epub 2016 May 7.

PMID:
27155850
13.

L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.

Pasanen A, Tuomi T, Isola J, Staff S, Bützow R, Loukovaara M.

Int J Gynecol Cancer. 2016 Oct;26(8):1465-1471. doi: 10.1097/IGC.0000000000000801.

PMID:
30814135
14.

L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.

Pasanen A, Tuomi T, Isola J, Staff S, Bützow R, Loukovaara M.

Int J Gynecol Cancer. 2016 Oct;26(8):1465-71. doi: 10.1097/IGC.0000000000000801.

PMID:
27648714
15.

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH.

BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2.

16.

Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.

Luhtala S, Staff S, Barok M, Tanner M, Isola J.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):212-219. doi: 10.1097/PAI.0000000000000406.

PMID:
27389555
17.

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.

Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H.

Breast Cancer Res Treat. 2016 Jun;157(3):437-46. doi: 10.1007/s10549-016-3835-7. Epub 2016 May 24.

18.

Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.

Luhtala S, Staff S, Tanner M, Isola J.

Tumour Biol. 2016 Jul;37(7):9813-23. doi: 10.1007/s13277-016-4870-z. Epub 2016 Jan 26.

PMID:
26810187
19.

[Clinical pathology on the verge of virtual microscopy].

Tolonen T, Näpänkangas J, Isola J.

Duodecim. 2015;131(21):1981-7. Finnish.

PMID:
26677548
20.

Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-Scanner.

Holmström O, Linder N, Lundin M, Moilanen H, Suutala A, Turkki R, Joensuu H, Isola J, Diwan V, Lundin J.

PLoS One. 2015 Dec 14;10(12):e0144688. doi: 10.1371/journal.pone.0144688. eCollection 2015.

21.

Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.

Helin HO, Tuominen VJ, Ylinen O, Helin HJ, Isola J.

Virchows Arch. 2016 Feb;468(2):191-8. doi: 10.1007/s00428-015-1868-7. Epub 2015 Oct 22.

PMID:
26493985
22.

Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology.

Laiho JE, Oikarinen S, Oikarinen M, Larsson PG, Stone VM, Hober D, Oberste S, Flodström-Tullberg M, Isola J, Hyöty H.

J Clin Virol. 2015 Aug;69:165-71. doi: 10.1016/j.jcv.2015.06.085. Epub 2015 Jun 23.

PMID:
26209400
23.

Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study.

Tolonen TT, Isola J, Kaipia A, Riikonen J, Koivusalo L, Huovinen S, Laurila M, Porre S, Tirkkonen M, Kujala P.

BMC Clin Pathol. 2015 Mar 8;15:4. doi: 10.1186/s12907-015-0001-9. eCollection 2015.

24.

Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.

Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.

Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.

PMID:
25706666
25.

Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.

Vassilev B, Sihto H, Li S, Hölttä-Vuori M, Ilola J, Lundin J, Isola J, Kellokumpu-Lehtinen PL, Joensuu H, Ikonen E.

Am J Pathol. 2015 Apr;185(4):987-1000. doi: 10.1016/j.ajpath.2014.12.018. Epub 2015 Feb 12.

PMID:
25681734
26.

Trastuzumab emtansine: mechanisms of action and drug resistance.

Barok M, Joensuu H, Isola J.

Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. Review.

27.

Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.

Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.

Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.

PMID:
24681744
28.

Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Saarelainen SK, Staff S, Peltonen N, Lehtimäki T, Isola J, Kujala PM, Vuento MH, Mäenpää JU.

Tumour Biol. 2014 May;35(5):4651-7. doi: 10.1007/s13277-014-1609-6. Epub 2014 Jan 14.

PMID:
24420153
29.

The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues.

Laurila R, Parkkila S, Isola J, Kallioniemi A, Alarmo EL.

Int J Clin Exp Pathol. 2013 Jun 15;6(7):1400-8. Print 2013.

30.

Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives.

Staff S, Kujala P, Karhu R, Rökman A, Ilvesaro J, Kares S, Isola J.

J Clin Pathol. 2013 Sep;66(9):807-10. doi: 10.1136/jclinpath-2012-201283. Epub 2013 Jun 8.

PMID:
23750036
31.

Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.

Falck AK, Bendahl PO, Ingvar C, Isola J, Jönsson PE, Lindblom P, Lövgren K, Rennstam K, Fernö M, Rydén L.

BMC Cancer. 2012 Sep 11;12:403. doi: 10.1186/1471-2407-12-403.

32.

Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.

Remes SM, Tuominen VJ, Helin H, Isola J, Arola J.

Am J Surg Pathol. 2012 Sep;36(9):1359-63. doi: 10.1097/PAS.0b013e3182632038.

PMID:
22895268
33.

Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.

Partanen L, Staaf J, Tanner M, Tuominen VJ, Borg Å, Isola J.

Genes Chromosomes Cancer. 2012 Sep;51(9):832-40. doi: 10.1002/gcc.21967. Epub 2012 May 14.

PMID:
22585709
34.

Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T.

J Pathol. 2012 Jul;227(3):336-45. doi: 10.1002/path.4027. Epub 2012 May 8.

PMID:
22431170
35.

ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry.

Tuominen VJ, Tolonen TT, Isola J.

Histopathology. 2012 Apr;60(5):758-67. doi: 10.1111/j.1365-2559.2011.04142.x. Epub 2012 Feb 1.

PMID:
22296215
36.

Long-term prognosis of breast cancer detected by mammography screening or other methods.

Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J.

Breast Cancer Res. 2011;13(6):R134. doi: 10.1186/bcr3080. Epub 2011 Dec 28.

37.

Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins.

Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S.

PLoS One. 2011;6(11):e27152. doi: 10.1371/journal.pone.0027152. Epub 2011 Nov 7.

38.

Overall and worst gleason scores are equally good predictors of prostate cancer progression.

Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T.

BMC Urol. 2011 Oct 6;11:21. doi: 10.1186/1471-2490-11-21.

39.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

40.

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H.

Breast Cancer Res. 2011 Sep 13;13(5):R87. doi: 10.1186/bcr2944.

41.

Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein.

Tothova V, Isola J, Parkkila S, Kopacek J, Pastorek J, Pastorekova S, Gibadulinova A.

J Cell Biochem. 2011 Nov;112(11):3373-84. doi: 10.1002/jcb.23268.

PMID:
21751241
42.

Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.

Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T.

BJU Int. 2011 Nov;108(9):1430-8. doi: 10.1111/j.1464-410X.2011.10253.x. Epub 2011 May 18.

43.

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Barok M, Tanner M, Köninki K, Isola J.

Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868.

44.

Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies.

Tolonen TT, Kujala PM, Laurila M, Tirkkonen M, Ilvesaro J, Tuominen VJ, Tammela TL, Isola J.

Hum Pathol. 2011 Nov;42(11):1635-42. doi: 10.1016/j.humpath.2010.12.021. Epub 2011 Apr 15.

PMID:
21497369
45.

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Barok M, Tanner M, Köninki K, Isola J.

Cancer Lett. 2011 Jul 28;306(2):171-9. doi: 10.1016/j.canlet.2011.03.002. Epub 2011 Apr 1.

PMID:
21458915
46.

[Targeted cytotoxic drugs emerging for cancer therapy].

Junttila TT, Tanner M, Isola J.

Duodecim. 2011;127(4):343-9. Review. Finnish.

PMID:
21442854
47.

Very high quantitative tumor HER2 content and outcome in early breast cancer.

Joensuu H, Sperinde J, Leinonen M, Huang W, Weidler J, Bono P, Kataja V, Kokko R, Turpeenniemi-Hujanen T, Jyrkkiö S, Isola J, Kellokumpu-Lehtinen PL, Paquet A, Lie Y, Bates M.

Ann Oncol. 2011 Sep;22(9):2007-13. doi: 10.1093/annonc/mdq710. Epub 2011 Feb 1.

PMID:
21285132
48.

Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.

Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J.

BMC Clin Pathol. 2011 Jan 25;11:3. doi: 10.1186/1472-6890-11-3.

49.

Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.

Lassus H, Staff S, Leminen A, Isola J, Butzow R.

Gynecol Oncol. 2011 Jan;120(1):11-7. doi: 10.1016/j.ygyno.2010.09.003. Erratum in: Gynecol Oncol. 2012 Apr;125(1):282-3.

PMID:
20937525
50.

Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland.

Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A.

Cancer Causes Control. 2010 Dec;21(12):2149-56. doi: 10.1007/s10552-010-9634-2. Epub 2010 Aug 21.

PMID:
20730482

Supplemental Content

Support Center